Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (February 2023)
19 slides from Moleculin Biotech's investor presentation, Feb 8, 2023
Slide 1: Moleculin Corporate Presentation February 2023
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Investment Highlights
Investment Highlights Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Portfolio with Focus Annamycin first and foremost. Two additional portfolios (STAT-3 inhibitors - WP1066 - and antimetabolites - WP112
Slide 4: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise =n sywenoy Gn S:MOLECULIN
Slide 5: Leveraging the Brightest Scientific Minds
\ Leveraging the Brightest Scientific Minds > HEMATOLOGY viROLOGY ~ ¢ be, PhO Marty Tallman, MD ficha * Memorial loan Kettering MDAnderson ‘Cancer [NIH)} Coneer Center Qo" y> & PANCREATIC c Hongbo Zhai, MD Wout University ‘School of Medicine Bmorecuun [TN 5
Slide 6: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECUNICAL PHASE 1 PHASE2 UPCOMING MILESTONES, Soft Tissue Sarcoma Lung Mets Annamycin ~ ‘Acute Myeloid Leukemia : WP1122 GBM, Other Tumors tify partner programin onco tof Pediatric Brain Tumors, Including DPIG Treatment of final Phase 1 pa Topline re
Slide 7: Additional Development Pipeline
Additional Development Pipeline ae Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECUNKAL PHASE 1 PHASE 2 UPCOMING MILESTONES Radiation wP1220 cre wp1122 Pancreat WP1122, WP1096, HIV, Hemorrhagic wp1097 T
Slide 8: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Demonstrated preliminary positive data in STS. ‘Announced RP2D and preliminary efficacy of 80% ORR in last cohort of single agent AML trial; Recent clearance in Italy brings active site total t
Slide 9: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline % of Mice with Heart Lesions Demonstrated to Be Non-Cardiotoxict Ability to overcome multi-drug resistance Organotrophic properties (e.g. >30x greater accumulation in lungs than doxorubicin) Potent topoisomerase-II poison with a wider z Concentration of Doxoru
Slide 10: Annamycin: Phase 1b/2 Study for STS Lung Mets
Annamycin Ongoing Phase 2 Portion of 1b/2 Study for Treatment of STS Lung Mets US Multi-Center, Open-Label, Dose Escalation Study Phase 1b Concluded Phase 2 Recruitment Open RP2D determined to Decreased RP2D to 330 g/m? be 360 mg/m? for improved tolerability Preliminary Phase 1b Data Showed No Cardi
Slide 11: Annamycin: Phase 1/2 Combination Study for R/R AML
Annamycin Phase 1/2 Combination Study for Treatment of NN Relapsed or Refractory (R/R) AML Poland/Italy Multi-Center, Open-Label, Dose Escalation Study 1, 2 & 3 with 21 days off Preclinical data tarabil Infusion days blished Primary Endpoint Met Pivoting to Phase 1/2 single agent trial established A
Slide 12: Annamycin: AML Clinical Benefit
Annamycin AML Clinical Benefit? . Subjects in Moleculin’s clinical trials 32 taken above the lifetime maximum anthracycline dose established by FDA * Up to 1800 mg/m? in AML study * Up to 1500 mg/m? in STS study (to date) 100% Ne cardiotoxicity has been seen in 42 subjects treated to date in Molecul
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside 41K 60K TNBCLung Panerestic Liver 67K aged RCC Lure ‘STS Lurg Mets ae Endometrial Lung Initial Annamycin 20,000 104K Targetindications } AcueMleid Potential Annamycin ome Liver TOTALINCIDENCE Expansion Indications TOTAL INCIDENCE 104K C
Slide 14: WP1066: Immune / Transcription Modulators
WP1066: Immune / Transcription Modulators STATS can be activated tough ‘many diferent pathways p-STAT3 inhibitor, a key cancer and viral ce signaling pathway Also inhibits c-Myc and HIF-1% Most published of our three portfolios Bmorecuun 4
Slide 15: WP1122: Phase 1a Study for COVID-19 also Accelerates Oncology Program
WP1122: Phase 1a Study for COVID-19 also Accelerates Oncology Program with RP2D Key Highlights Prodrug of glucose decoy enables drug-ike properties Targets glycolysis and glycosylation; limits viral infe and replication Clinical Highlights Ongoing effort to identify partners to potentially fund furt
Slide 16: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations Beyond Mid-2024! ~$50.4M Cash Balance? ~$36M Market Cap? ~28.6M Shares Outstanding* Bmorecuun ae 16
Slide 17: Multiple Milestones And Key Data Readouts
Multiple Milestones And Key Data Readouts Expected In 2023 C ) STS (US) STS (EU) AML AML ° ° 6 ° Phase 2 Phase 1b/2 Commence Dosing Publish CSR Interim Data Interim in Phase 1/2 Ara-C for MB-105 Data combination study Phase 1 Results WP1122/ Arenaviruses GBM Pediatric Brain Tumors WP1096/ © e@ e WP1
Slide 18: Investment Summary
Investment Summary Annamycin inhibitor , four ongoing or potential Phase 2 ing human data in the near future Pipeline Expansion Potential successin lead programs fu ‘expansion into additional high-value Global Network Sufficient capital to fund = operations beyond mid-2024! ible pipeline y indicatio
Slide 19: Thank You!
Thank You! 0 8, oo {MOLECULIN oar
Moleculin Biotech — Investor Presentation (February 2023) on 6ix